International Application No PCT/GB2004/004783

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K39/39 A61P9/00 A61P37/	00 A61P37/06						
According to	International Patent Classification (IPC) or to both national classifica	ation and IPC						
B. FIELDS	SEARCHED							
Minimum do IPC 7	cumentation searched (classification system followed by classification $A61\mathrm{K}$	on symbols)						
	ion searched other than minimum documentation to the extent that s	·						
Electronic da	ata base consulted during the international search (name of data base	se and, where practical, search terms used)						
EPO-Internal, BIOSIS, EMBASE, WPI Data								
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT							
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.					
Х	WO 03/049752 A (INSTITUT PASTEUR NATIONAL DE LA SANTE ET DE LA RE MED) 19 June 2003 (2003-06-19) page 4, lines 22-27 page 6, lines 5-8 claims 1,3,5,15,16	; INSTITUT CHERCHE	1-8, 11-19,23					
A	AU 706 122 B2 (UNIVERSITY COLLEG 10 June 1999 (1999-06-10) page 4, lines 3-22; claims 1-3,9 examples 2,4		1-23					
X Furth	ner documents are listed in the continuation of box C.	X Patent family members are listed	л алпех.					
"A" docume consid	tegories of cited documents: ent defining the general state of the art which is not lered to be of particular relevance	"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention						
"E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled						
other of docume later the	neams on the international filing date but nan the priority date claimed	in the art. *&* document member of the same patent family						
Date of the	actual completion of the international search	Date of mailing of the international sea	rch report					
1	3 June 2005	07	A7 2005					
Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer						

International Application No
PCT/GB2004/004783

		PCT/GB2004/004783
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CONFORTI ANITA ET AL: "Specific and long-lasting suppression of rat adjuvant arthritis by low-dose Mycobacterium butyricum" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 324, no. 2-3, 1997, pages 241-247, XP002319250 ISSN: 0014-2999 abstract	1,5-7, 12,14, 17-19
A	WO 85/05034 A (UNIVERSITY COLLEGE LONDON; YEDA RESEARCH AND DEVELOPMENT CO. LTD) 21 November 1985 (1985-11-21) abstract page 2, lines 3-9 page 2, lines 15-22 page 5, line 24 - page 6, line 7 claims 1,6,10	1-23
P,X	WO 2004/022093 A (UNIVERSITY COLLEGE LONDON; MCINTYRE, GRAHAM; STANFORD, JOHN, LAWSON; S) 18 March 2004 (2004-03-18) the whole document	1-23

International application No. PCT/GB2004/004783

Box II	Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)							
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:							
1. X	Claims Nos.: 24-25 because they relate to subject matter not required to be searched by this Authority, namely:							
	Although claims 12-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.							
2. X	Claims Nos.: 24-25 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210							
3	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).							
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)							
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:							
	see additional sheet							
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.							
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.							
з. 🗶	As only some of the required additional search fees were timely pald by the applicant, this International Search Report covers only those claims for which fees were pald, specifically claims Nos.:							
	1-23(partially)							
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:							
Remark	on Protest The additional search fees were accompanied by the applicant's protest.							
	X No protest accompanied the payment of additional search fees.							

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Rhodococcus for the treatment or prevention of autoimmune diseases or disorders

2. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Gordonia for the treatment or prevention of autoimmune diseases or disorders

3. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Nocardia for the treatment or prevention of autoimmune diseases or disorders

4. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Dietzia for the treatment or prevention of autoimmune diseases or disorders

5. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Tsukamurella for the treatment or prevention of autoimmune diseases or disorders

6. claims: 1-23 (partially)

use of an immune modulator composition comprising a whole cell bacterium from the genus Nocardioides for the treatment or prevention of autoimmune diseases or disorders

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 12-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 24-25

Claims 24-25 do not have additional technical features and therefore, these claims were not searched

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

Information on patent family members

International Application No PCT/GB2004/004783

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 03049752	A	19-06-2003	AU BR CA EP WO	2002356387 A1 0214902 A 2469334 A1 1461054 A2 03049752 A2	23-06-2003 30-11-2004 19-06-2003 29-09-2004 19-06-2003
AU 706122	B2	10-06-1999	ATTUUUGRAZEE AATUUUGRAZEE AATUUGAATU	151641 T 192046 T 675421 B2 3637793 A 7188796 A 99054 A 9305946 A 2130117 A1 9402023 A3 69309915 D1 69308503 D1 69328503 D1 69328503 T2 630259 T3 763361 T3 0630259 A1 0763361 A2 2104131 T3 2145968 T3 9316727 A1 3024113 T3 2145968 T3 9316727 A1 3033772 T3 69941 A2 7506093 T 275862 B1 943082 A 249518 A 117833 B 2124367 C1 99994 A3 5885588 A	15-05-1997 15-05-2000 06-02-1997 13-09-1993 06-02-1997 28-08-1995 21-10-1997 02-09-1993 15-02-1995 22-05-1997 24-07-1997 31-05-2000 24-08-2000 24-08-2000 24-08-2000 28-12-1994 19-03-1997 01-10-1997 16-07-2000 02-09-1993 31-10-2000 28-09-1995 06-07-1995 15-12-2000 17-10-1994 27-07-1997 30-08-2002 10-01-1999
WO 8505034	A	21-11-1985	AT AU AU DE EP WO JP JP US	55252 T 588809 B2 4297685 A 3579113 D1 0181364 A1 8505034 A1 7051509 B 61502258 T 4716038 A	28-11-1985 13-09-1990 21-05-1986
WO 2004022093	Α	18-03-2004	AU CA EP WO	2003263319 A1 2497644 A1 1534330 A1 2004022093 A1	18-03-2004 01-06-2005